NCT01436617

Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 303 (actual)
• Sponsor: Centre Francois Baclesse · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this study is to validate the utility of IgE anti-cetuximab in the treatment strategy to identify patients at risk for a severe allergic reaction to cetuximab (grade 3 or 4 of the classification of NCI) and thus reduce the incidence of severe reactions.

Conditions

• Colon Cancer
• Head and Neck Cancer
• Allergic Reaction

Interventions

Type	Name	Description
OTHER	blood sample	The IgE anti cetuximab test will then be conducted by an ELISA test

Timeline

• Start date: 2010-01-01
• Primary completion: 2013-03-01
• Completion: 2013-03-01
• First posted: 2011-09-19
• Last updated: 2013-03-08

Locations

10 sites across 1 country: France